630421-73-7

Basic information

• Product Name: 1,6-DICHLORO-ISOQUINOLINE
• Synonyms: 1,6-DICHLORO-ISOQUINOLINE;Isoquinoline, 1,6-dichloro-
• CAS NO: 630421-73-7
• Molecular Formula: C₉H₅Cl₂N
• Molecular Weight: 198.05
• EINECS: 200-258-5
• Mol File: 630421-73-7.mol

Chemical Properties

• Boiling Point: 327.7 °C at 760 mmHg
• Flash Point: 182 °C
• Appearance: /
• Density: 1.407 g/cm³
• Vapor Pressure: 0.000378mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.48±0.38(Predicted)
• CAS DataBase Reference: 1,6-DICHLORO-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-DICHLORO-ISOQUINOLINE(630421-73-7)
• EPA Substance Registry System: 1,6-DICHLORO-ISOQUINOLINE(630421-73-7)

Safety Data

• Hazardous Substances Data: 630421-73-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,6-Dichloro-isoquinoline is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 1,6-Dichloro-isoquinoline is employed as a precursor in the production of agrochemicals, aiding in the creation of compounds that protect crops and enhance agricultural productivity.
Used in Dye Manufacturing:
1,6-Dichloro-isoquinoline is used as a chemical intermediate in the manufacture of dyes, playing a role in the coloration processes for textiles, plastics, and other materials.
Used in Organic Compounds Synthesis:
1,6-DICHLORO-ISOQUINOLINE serves as an intermediate in the synthesis of other organic compounds, facilitating the creation of a wide range of chemical products for various applications across different industries.

InChI:InChI=1/C9H5Cl2N/c10-7-1-2-8-6(5-7)3-4-12-9(8)11/h1-5H

Upstream product

• 252061-78-2 isoquinoline-1,6-diol 
• 10025-87-3 trichlorophosphate 
• 131002-09-0 6-chloroisoquinolin-1(2Η)-one 
• 62882-02-4 6-chloroisoquinoline 

Downstream Products

• 1179149-30-4 6-chloroisoquinoline-1-carboxylic acid 
• 1620789-20-9 C₁₅H₁₀ClN 
• 1620789-21-0 C₂₆H₂₃NO 
• 1620789-22-1 C₂₈H₂₇NO 
• 1620789-23-2 C₂₇H₂₃N 
• 1620789-26-5 C₂₆H₂₃NO 
• 1620789-27-6 C₂₈H₂₇NO 
• 1620789-28-7 C₂₇H₂₃N 
• 1620789-25-4 C₁₉H₁₈ClN 

Relevant articles and documents

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula (I) are provided or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer, and osteolytic bone disorders.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.